UCLH Trust Product Uptake

Advanced Medical Solutions Grp PLC
16 August 2007


For immediate release                                           16 August 2007



                      Advanced Medical Solutions Group plc

                            ('AMS' or 'the Company')



          Major London Teaching Hospital Trust implements ActivHeal(R)



                     Trading Update / Interim Results Date



Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global
medical technology company, today announces that following a review of their
woundcare product formulary, University College London Hospitals (UCLH) NHS
Foundation Trust has adopted products from the ActivHeal(R) advanced woundcare
product range and these are now in routine use.



Granted Foundation Trust status in 2004 and comprising seven separate hospital
sites, UCLH NHS Trust is a major London teaching centre and contracts with 300
Primary Care Trusts.



ActivHeal(R) is a value range of products provided directly to the NHS by AMS as
a first line therapy for routine wounds.  These complement the use of its new
technologies such as silver alginate for treating more difficult wounds which
are sold through strategic partners.



The ActivHeal(R) range offers equivalent technical and clinical performance to
similar branded products but at a substantially reduced cost thereby delivering
real and immediate savings to the NHS.  This saving is estimated to be of the
order of £25 million per year in the UK which helps to balance budgets and
afford new technologies for problematic cases.  At the end of 2006 over 40 NHS
Hospital and Primary Care Trusts were using ActivHeal(R) and this number is
increasing steadily.



Trading update and Interim Results announcement date:



The Company will announce its Interim Results for the six months ended 30th June
2007 on Tuesday 4th September 2007 which, as indicated in the trading
announcement on 6th June 2007, are expected to show maiden first half profits.
Since then trading has continued to be strong and a further update will be given
on 4th September.



An analyst briefing will be held at 10:00 am at Buchanan Communications, 45,
Moorfields, London EC2 on the day of the announcement.



Advanced Medical Solutions Group plc confirms that, for the purposes of AIM Rule
26, the Company's website address is http://www.admedsol.com/corporate/Aim26/
index.html



Commenting on this announcement, Dr. Don Evans, Chief Executive of AMS, stated:
'I am delighted that we have added a major teaching centre such as UCLH to the
growing number of Trusts that have adopted the ActivHeal(R) offering as a way of
managing costs without compromising patient care.'



Sarah Lewis, Tissue Viability Nurse, UCLH, added: 'Following a review of our
woundcare product formulary, the dressings review group evaluated products from
a number of companies.  After a three month user trial, ActivHeal(R) products
were added to our formulary based on evidence presented to the Use of Medicines
Committee.   We have not experienced any problem with the products.



'The AMS clinical nurse team assisted us in making a successful implementation
with product training throughout the Trust, provision of posters, woundcare
education modules and by running a study day.'

                                   -- ENDS --



For further information, please contact:


Advanced Medical Solutions Group plc                    [phone]
Don Evans (Chief Executive Officer)
Mary Tavener (Group Finance Director)
www.admedsol.com

Buchanan Communications                                 [phone]
Mark Court/Mary-Jane Johnson

Landsbanki Securities (UK) Ltd                          [phone]
Shaun Dobson / Xavier DeMol





Notes for Editors:



Advanced Medical Solutions is a UK based company developing and providing
leading edge technology to the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, the Company is focused on the design,
development, manufacture and sale of advanced woundcare dressings and products
for closing wounds and sealing tissue.

AMS provides a full range of advanced woundcare products for sale in hospital,
nursing home and community care markets.  The main indications are for chronic
wounds such as ulcers and pressure sores.  These products pioneer the concept of
moist wound healing to allow wounds to heal faster and with less pain and
scarring if they remain moist.  They protect the wound, deal with tissue fluids
and provide an optimal environment for healing to occur.   AMS' resources ensure
a unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move a product from design and development through to production and delivery
ready for distribution into customer markets.

The acquisition of MedLogic in 2002 has brought AMS products based upon
cyanoacrylate adhesive technology which allow the closure of wounds following
trauma or surgical incisions, or seal skin to protect against breakdown or wound
infection.  These products address the emerging tissue adhesives and sealants
segment of the wound closure market.



AMS' technology and products currently serve the majority of the key global
markets and strategic partners.


                      This information is provided by RNS
            The company news service from the London Stock Exchange